Most pages on this site have to explain that the evidence is preclinical. This one does not. TUDCA was tested in hepatitis C in randomised, placebo-controlled human trials in the 1990s, and those trials are among the largest human efficacy studies this compound has ever had for anything.
They are also the clearest illustration on the whole site of a distinction that matters everywhere else: the difference between improving a number and improving a disease. TUDCA did the first. A Cochrane systematic review looked at whether it did the second, and the answer is worth reading in full.
One thing belongs at the very top. Chronic hepatitis C is now curable in most people with direct-acting antiviral drugs taken for eight to twelve weeks. Nothing on this page is a reason to use a bile acid instead of asking about treatment that clears the infection.
Key Takeaways
- A multicentre, randomised, placebo-controlled trial gave 150 patients with chronic hepatitis TUDCA at 500 mg or 750 mg daily, or placebo, for 6 months[1].
- Aminotransferases fell consistently on TUDCA compared with placebo at p below 0.001, and improved progressively over time[1]. The authors’ own conclusion was that TUDCA improves the biochemical expression of chronic hepatitis, and that long-term studies with clinically relevant endpoints were warranted.
- A 2003 Cochrane review pooled 27 randomised trials of bile acids in hepatitis B or C and reported that none was of high methodological quality[2].
- Across 25 chronic hepatitis C trials, bile acids did not reduce the risk of still having detectable HCV RNA, at a relative risk of 0.99 with a 95 percent confidence interval of 0.91 to 1.07[2]. The virus was unaffected.
- Bile acids did reduce the risk of an abnormal ALT at the end of treatment, relative risk 0.82, confidence interval 0.76 to 0.90[2].
- In the same review, bile acids significantly increased the Knodell histology score, a weighted mean difference of 0.20 with a confidence interval of 0.08 to 0.31[2]. A higher score is worse liver histology, not better.
- No severe adverse events were reported in any of the pooled trials[2].
Why Bile Acids Were Tried Against a Virus at All
The reasoning was not antiviral. In HCV-related chronic hepatitis, bile duct damage and some degree of cholestasis are frequently visible on biopsy, and TUDCA was already an established treatment for chronic cholestatic liver disease. The hypothesis was that a drug which helps cholestatic injury might help the cholestatic component of a necroinflammatory disease[1].
TUDCA specifically was chosen over its parent compound because it has more favourable physicochemical and metabolic properties than ursodeoxycholic acid, the difference covered on the TUDCA versus UDCA page. This is one of the few clinical settings where somebody actually tested that preference in people rather than asserting it.
So nobody expected the virus to go away. The endpoints were liver injury markers, and that framing is the key to reading the results honestly.
The 1998 Trial
The trial was published in Hepato-gastroenterology in 1998, led by Crosignani and colleagues across multiple Italian centres[1]. One hundred and fifty patients with chronic hepatitis were randomly assigned to TUDCA at 500 mg daily, TUDCA at 750 mg daily, or placebo, for six months.
A consistent decrease in serum aminotransferase levels was observed in the TUDCA groups compared with placebo, at p below 0.001, and there was a progressive improvement with time, reported as a linear time effect at p below 0.05. In other words the enzymes did not simply drop and plateau; they kept falling over the six months.
For a supplement literature dominated by rodents, this is a serious study. It is randomised, placebo-controlled, multicentre, of a respectable size, with a six-month duration and two dose arms. Very little else on this site can say the same.
The authors’ conclusion is careful and worth quoting in substance: TUDCA improves the biochemical expression of chronic hepatitis, and long-term studies with clinically relevant endpoints are warranted. They claimed a change in the blood tests and explicitly flagged that the outcomes patients care about had not been measured.
A second Italian paper the following year examined TUDCA’s effect on ALT, GGT and viral load in HCV-related chronic hepatitis with reference to genotype[3]. It is indexed in PubMed without an abstract, so beyond what its title states there is nothing that can responsibly be reported from it here, and no finding on this page rests on it.
What the Cochrane Review Found
In 2003 the Cochrane Hepato-Biliary Group published a systematic review of bile acids for viral hepatitis[2]. It identified 27 randomised trials in hepatitis B or C and stated plainly that none of them was of high methodological quality. Twenty-five of those trials were in chronic hepatitis C, of which 21 used UDCA and four used tauro-UDCA, so TUDCA is a minority of the pooled evidence.
On the virus, nothing. Bile acids did not significantly reduce the risk of having detectable serum HCV RNA at the end of treatment, relative risk 0.99 with a confidence interval of 0.91 to 1.07. That interval is tight and centred on no effect. Bile acids also did not reduce cirrhosis or the portal and periportal inflammation score.
On the enzymes, the 1998 result held up. Bile acids significantly reduced the risk of an abnormal serum ALT at the end of treatment, relative risk 0.82, confidence interval 0.76 to 0.90, and the benefit persisted at follow-up at 0.91, interval 0.85 to 0.98. So the biochemical effect is real and reproducible across many trials.
And then the finding that almost never appears in any summary of this literature. Bile acids significantly increased the Knodell score at the end of treatment, a weighted mean difference of 0.20 with a confidence interval of 0.08 to 0.31. The Knodell histology activity index scores liver biopsy damage, and higher means worse. The pooled histology moved, slightly but statistically significantly, in the wrong direction.
The reviewers’ bottom line was that bile acids lead to a significant improvement in serum transaminase activities in hepatitis B and C, and that there is insufficient evidence either to support or to refute effects on viral markers, mortality, incidence of cirrhosis, or liver histology. They called for trials of high methodological quality. No severe adverse events were reported.
The Lesson That Generalises Beyond Hepatitis
A great deal of TUDCA’s reputation rests on lowering liver enzymes, and this is the one disease where that effect has been demonstrated in a randomised human trial and then confirmed in a pooled analysis of twenty-five more. It is also the one disease where somebody went on to check whether the underlying liver damage improved, and the pooled answer was no, with the point estimate slightly unfavourable.
That is the single most important caveat to carry to any other page on this site. ALT is a marker of hepatocyte membrane leakage, not a measure of fibrosis, inflammation grade or prognosis. A compound can reduce enzyme release without altering the disease, and in this instance one apparently did. Anyone using their own liver panel to judge whether TUDCA is working should understand that the only time this was tested properly, the panel and the biopsy disagreed.
It is worth being fair to the compound too. The Knodell difference is small, none of the pooled trials was high quality, and the review is from 2003. The honest reading is not that TUDCA harms the liver in hepatitis C; it is that the evidence is not good enough to say it helps, and the one histological signal available does not point the way the enzyme data do.
Where This Leaves Someone With Hepatitis C Today
In a completely different place from the patients in these trials, because the disease is now curable. Direct-acting antivirals clear HCV in the large majority of people treated, and cure removes the driver of the liver injury rather than adjusting a marker of it. Anyone with chronic hepatitis C who is not on treatment should be asking about that, not about bile acids.
If you have hepatitis C and are already taking TUDCA, the relevant points are that no severe adverse events appeared across 27 pooled trials[2], that the side effect profile is mild, and that interactions matter because antiviral regimens are sensitive to what else is in the system. Tell the prescriber.
And for the broader audience: this is not a reason to dismiss TUDCA. Its best-supported use remains cholestatic liver disease, where the primary biliary cholangitis trials are a better-matched literature. It is a reason to be precise about which claim the evidence supports, because in hepatitis C the honest claim is narrow and the popular one is not.
Nothing on this page is medical advice. Chronic hepatitis C is a treatable, usually curable infection, and anyone who has it should be discussing antiviral treatment with a clinician rather than managing it with a supplement.
Frequently Asked Questions
Does TUDCA treat hepatitis C?
It lowers liver enzymes and does not affect the virus. In a randomised placebo-controlled trial of 150 patients, TUDCA at 500 or 750 mg daily for 6 months reduced aminotransferases at p below 0.001[1]. A Cochrane review of 25 chronic hepatitis C trials found bile acids did not reduce detectable HCV RNA, relative risk 0.99 with a confidence interval of 0.91 to 1.07[2]. Hepatitis C is now usually curable with direct-acting antivirals, which is the treatment to ask about.
How much TUDCA was used in the hepatitis trials?
Either 500 mg or 750 mg daily for six months, compared against placebo, in 150 patients with chronic hepatitis[1]. Both arms showed the aminotransferase reduction. This is one of the few human dose figures that comes from a randomised trial rather than from animal work, though it was set for a liver injury endpoint rather than titrated for a general-purpose dose.
Did TUDCA improve liver biopsies in hepatitis C?
No. In the pooled Cochrane analysis, bile acids significantly increased the Knodell histology score at the end of treatment, a weighted mean difference of 0.20 with a confidence interval of 0.08 to 0.31, and a higher Knodell score means worse histology[2]. Portal and periportal inflammation scores and cirrhosis were also unchanged. The reviewers concluded there was insufficient evidence to support or refute an effect on liver histology.
Why do liver enzymes fall if the disease does not improve?
ALT rises when hepatocyte membranes leak, so it measures ongoing cell injury rather than the amount of fibrosis or the grade of inflammation. A compound that stabilises those membranes can reduce enzyme release while the underlying disease process continues. Hepatitis C is the one condition where both were measured on bile acids, and they gave different answers[2], which is why a falling ALT alone is weak evidence that any liver supplement is working.
References
- Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology (1998).
- Bile acids for viral hepatitis. Cochrane Database Syst Rev (2003).
- Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype. Ital J Gastroenterol Hepatol (1999).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
